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iragu: a novel inducible and 
reversible Mouse Model for 
Ubiquitous recombinase activity
Marie Bonnet†, Leonor Morais Sarmento†, Ana C. Martins, Daniel Sobral, Joana Silva and 
Jocelyne Demengeot*
Instituto Gulbenkian de Ciência, Oeiras, Portugal
Developing lymphocytes express the recombination activating genes (RAGs) 1 and 
2 products that form a site specific recombinase complex (RAG), introducing double 
strand DNA breaks (DSBs) at recombination signal sequences (RSSs) flanking the V, 
D, and J gene segments in the antigen receptor loci. The subsequent steps in the 
reaction consist in the ligation of DSBs by ubiquitous enzymes of the non-homolo-
gous end joining DNA repair pathway. This mutagenesis process is responsible for the 
generation of the very large clonal diversity of T and B lymphocytes, itself allowing the 
recognition of a virtually open-ended antigenic universe. Sequences resembling RSS 
are found at high frequency all over the genome, and involved in RAG mediated illegit-
imate recombination and translocations. Hence, natural and induced ectopic activity 
of RAG is a threat to the genome only recently underscored. Here, we report and 
characterize a novel mouse transgenic system for which ubiquitous expression of the 
recombinase is inducible. In this system, the RAG1 protein is constitutively expressed 
and functional, while the RAG2 protein, coupled to the estrogen receptor, becomes 
functionally active upon 4-hydroxytamoxifen (TAM) administration. We describe two 
transgenic lines. The first one, when introgressed into an endogenous Rag2−/− genetic 
background is faithfully recapitulating lymphocyte development, repertoire dynamics 
and cryptic rearrangements, in a TAM-dependent manner. In this model, deprivation of 
TAM is followed by lymphocyte development arrest, evidencing the reversibility of the 
system. The second transgenic line is leaky, as the transgenes promote lymphocyte 
differentiation in absence of TAM treatment. Upon TAM-induction defects in lympho-
cytes composition and global health reveals the deleterious effect of uncontrolled RAG 
activity. Overall, this novel transgenic model provides a tool where RAG activity can be 
specifically manipulated to assess the dynamics of lymphocyte differentiation and the 
challenges imposed by the recombinase on the vertebrate genome.
Keywords: recombination activating gene, transgenic mouse model, 4-hydroxytamoxifen induction, estrogen 
receptor, lymphocyte development, V(D)J recombination
inTrODUcTiOn
B and T lymphocytes are the prerogative of the adaptive immune system thanks to their ability to 
generate a quasi-infinite diversity of antigen receptors through a mechanism called V(D)J recom-
bination. This process consists in the rearrangement of somatic DNA, to combine one variability 
(V), possibly a diversity (D), and one joining (J) gene segments together, and comes down to the 
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cutting of the segments by the recombinase complex and the 
pasting of the broken ends by the ubiquitous non-homologous 
DNA end-joining repair machinery (NHEJ), within an accessible 
region called the recombination center [(1)]. Imprecise joining 
and repair of the gene segments coding ends (CEs) by the NHEJ 
machinery produce the coding joint (CJ), therefore, adding junc-
tional diversity by removing template nucleotides and adding CG 
rich de novo nucleotide at the junction of the two gene segments 
(2). On the other side, the two signal ends are ligated together 
without any editing to form the signal joint (SJ). Both the CJ and 
the SJ determine the recombinase-dependent signature of the 
V(D)J recombination mechanism (3).
The recombinase complex is formed by the two lymphoid-
specific recombination activating genes (RAG1 and 2) proteins, 
which are sufficient to induce a double strand DNA break, provided 
the gene segments are flanked by functional recombination signal 
sequences [RSSs; (4)], which are the specific target sequences of 
the recombinase. RSSs are long and considerably degenerated 
sequences, a feature that may favor a wide range of interactions 
with RAG and consequently a differential segment usage in the 
repertoire of antigen receptor genes. In turn, this permissiveness 
in nucleotide sequences results in an abundant distribution all 
over the genome of sequences resembling RSS—called cryptic 
RSS [cRSS; (5, 6)]—which can be occasionally recognized by the 
recombination machinery and involved in translocation events 
(7). Actually, illegitimate V(D)J recombination events involv-
ing proto-oncogenes and B or T cell receptors (BCR and TCR, 
respectively) loci are found in most lymphoid leukemias (8, 9). 
More recently, cRSS and their accessibility to RAG were formally 
quantified and their purging in vertebrates genomes shown to be 
limited only to specific gene regions (10, 11). The very tight regu-
lation of RAG expression in developing lymphocytes may well 
limit unwanted recombination events. In turn, ectopic expression 
of RAG in non-lymphoid tissues, as occasionally reported in solid 
tumors [e.g., Ref. (12)], may favor genome alterations.
Both RAG proteins are necessary to the recombination reac-
tion, as shown by the complete absence of rearrangements of 
antigen receptor genes, and ensuing lack of mature lymphocytes, 
when either of the two genes is knocked out (13, 14). RAG1 
and 2 also drive each step of the recombination reaction by the 
way they bind DNA, keep broken ends within the recombinase 
complex and trigger repair of DNA ends by recruiting the NHEJ 
machinery (15–18). The recombinase complex is tightly regulated 
at tissue, cellular and molecular levels. First, RAG1 and 2 are 
both expressed only in lymphocytes, though one or the other are 
expressed at low levels in different non-lymphoid tissues (19–21). 
Second, RAG expression is downregulated throughout the G1/S 
phase of the cell cycle and during the cell divisions following the 
recombination of an antigen receptor locus (22, 23), which occur 
primarily after the production of a functional heavy chain of 
antigen receptor (TCRβ, TCRδ, and IgH loci) and secondly after 
the expression and the pairing of the light chain to the heavy 
chain (TCRα, TCRγ, and Igλ or Igκ, respectively) to form the cell 
surface receptor. And third, the recombinase specifically targets 
each locus in the appropriate lineage and development stage. For 
example, this is how the TCRβ locus complete recombination 
occurs in T cells only, before recombination of the TCRα locus 
and that a single functional TCRβ is produced per cell, which is 
called allelic exclusion (24). This last regulation level is driven 
by changes in chromatin accessibility of the antigen receptor loci 
that become accessible to the recombinase at the right juncture, 
to ensure proper lymphocyte development (23).
Recombinase deficiency can be spotted at the level of lymphoid 
cell differentiation by flow cytometry, by looking at the con-
comitant expression of cell surface markers to the developmental 
stages. Thus, V(D)J recombination occurs at the DN3 (CD25+
CD44−CD4−CD8−) and DP (CD4+CD8+) stages of T cell devel-
opment for the TCRβ and TCRα rearrangements, respectively, 
and RAG-deficient mice exhibit a complete block of thymocytes 
development at the DN3 stage. Regarding B-cell development, as 
complete recombination of the IgH is required for the transition 
to the C′ fraction (B220+CD43+BP1+), RAG-deficient mice show a 
block of development at the pre-B C fraction (B220+CD43+BP1−), 
and the absence of IgM+ cells (fractions E and F) (25).
To assess the significance of the strict tissue and developmental 
stage specificities of the rag genes expression, we had previously 
generated transgenic mice in which both rag genes were consti-
tutively coexpressed (26) and we reported a premature death of 
transgenic animals before 4 weeks of age, which was associated 
with severe lymphopenia.
To overcome this development constrain, we developed a new 
inducible model for ubiquitous expression of the recombinase. 
Schatz and coll. had produced an inducible model of RAG 
activity, which was dependant on tetracycline removal (27). 
Our system is more straightforward in the sense that RAG1 is 
constitutively expressed and functional, while RAG2 is coupled 
to the estrogen receptor (ER), which maintains the RAG2tg 
sequestered in a cytoplasmic complex and renders the rag2tg non 
functional. 4-Hydroxytamoxifen (TAM) administration uncou-
ples the ER-domain from the RAG2 proteins, which can be then 
translocated to the nucleus and become functionally active (28). 
We describe this new RAG-inducible and reversible transgenic 
model. Using transgenic mice crossed on the RAG2-deficient 
background, we show that the rag1 and rag2-ER transgenes are 
ubiquitously expressed, that their activity rescues the develop-
ment of B and T  lymphocytes upon TAM-administration, and 
that this induction is reversible. We also show that RAG trans-
genic activity is functional in non-lymphoid tissues. We describe 
another line of transgenic mice that is leaky, and which exhibits 
defects of lymphocyte development.
MaTerials anD MeThODs
Description of the constructs
H2K-RAG1 and H2K-RAG2ERTAM constructs were previously 
described (29).
Mouse line and Treatment for induction
Wild-type (WT) and RAG2-deficient (R2−/−) used in this study 
were originally purchased from Jackson Laboratory (Bar Harbor, 
ME, USA), bred and maintained under specific pathogen-free 
(SPF) conditions at the IGC animal facility, Portugal. Also, 
RAG1tg/RAG2tg-ER mice have been established by coinjection 
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of the cut rag1tg and rag2tg-ER fragments into C57/Bl6 or 
FVB oocytes. Transgenic founders were identified by PCR (see 
primers sequences and PCR conditions in Tables S1 and S2 in 
Supplementary Material). We obtained one line in the C57/Bl6 
background that gave progeny (hereafter Tg), which we crossed 
on a R2−/− background. Additional two lines generated on the Fvb 
background were then backcrossed on the C57/Bl6 background. 
The functionality of the RAG2tg-ER was induced by tamoxifen 
food (CRD TAM400/CreER, Teklad, hereafter TAM) adminis-
tration, when mice were 5–7 weeks old. For the FACS analyses 
of the phenotypes, mice were fed 4 weeks with TAM only. For 
maintained RAG2 activity, transgenic mice were fed 4 weeks with 
TAM, followed by alternation periods of normal versus TAM 
food. As for the analysis of the reversibility of the system, mice 
were either kept under TAM during 1 week and then fed with 
normal food during 3 weeks, or for 2 weeks on TAM followed by 
1 month of normal food.
For bone marrow adoptive transfer, R2−/− recipient mice were 
sub-lethally irradiated (900 rad) and reconstituted the following 
day with 5 millions of total bone marrow cells from transgenic 
or R2−/− mice, injected into the retro-orbital plexus. Normal 
food and Tam food were given by alternation every week. All 
mice experimental protocols were in accordance with European, 
Portuguese and Instituto Gulbenkian de Ciência ethical commit-
tee animal guidelines.
nucleic acid analyses
For transcription analysis, cell suspensions from different organs 
from WT and Tg R2−/− mice were generated by mechanical 
disruption of the organs and proteinase K digestion. RNA was 
performed using RNAeasy kit (Qiagen) as recommended by 
the manufacturer and cDNA was synthesized as described (30). 
PCR for the beta-tubulin was performed to assess for the nucleic 
acid loads, and specific PCR for endogenic and transgenic rag1 
and rag2 were used to determine mRNA levels of each sample. 
Primer sequences and optimal PCR conditions for each PCR 
test are shown in Tables S1 and S2 in Supplementary Material, 
respectively.
We analyzed the Jα usage for the VJα rearrangements as 
described (31). Briefly, total cDNA was generated from mRNA 
from total thymocytes from WT and Tg endoR2−/− mice. Semi-
nested PCR using degenerated oligos for the Vα segments were 
used (31) in which EcoRI and XhoI restriction sites were added. 
PCR fragments were either purified and cloned into EcoRI/
XhoI cut pKS vector and sent for sequencing or directly sent 
for high-throughput sequencing with a MiSeq sequencer, both 
at the IGC sequencing platform. Reads are available at: https://
www.ncbi.nlm.nih.gov/bioproject/PRJNA400571. Original raw 
paired reads were quality filtered with seqtk (trimfq-q 0.01) 
and merged with flash. Both merged and unmerged reads were 
pooled together to pass to the MiTCR software version 1.0.3 (32), 
using the following command: java-jar-Xmx2G-jar mitcr.jar-
pset flex-species mm-gene TCRab_S1S5_filtered_001.all.fastq 
TCRab_S1S5_filtered_001.all.mitcr.cls, where TCRab_S1S5_fil-
tered_001.all.fastq and TCRab_S1S5_filtered_001.all.mitcr.cls 
are the input and output files, respectively.
For Bcl11b cryptic recombination analysis, genomic DNA from 
total thymocytes was prepared by phenol/chloroform extraction 
and PCR conditions were as described previously (33) to amplify 
the cryptic rearrangement events. We performed fluctuation 
PCR by repeating several times (12 or 24) the same amplification 
with either 60 or 240 ng of DNA for Tg endoR2−/− TAM+ and 
Tg endoR2+/− TAM+ mice, respectively (34). PCR fragments were 
sequenced on the IGC sequencing platform.
Flow cytometry
Single-cell suspensions from thymus, lymph nodes, bone marrow, 
and peripheral blood mononuclear cells (PBMCs) were prepared, 
counted, and stained as described previously (35). Briefly, 1 × 106 
cells per sample were pre-incubated with Fc-block anti-CD16/
CD32 followed by staining incubation for 45  min at 4°C with 
fluorochrome-conjugated antibodies (Antibodies listed in Table 
S3 in Supplementary Material), before washes. Data were acquired 
on FACS CyAn™ ADP, using Summit™ software (Beckman 
Coulter) and analyzed using FlowJo (Tri Star Inc.). Doublets and 
clumps were excluded from analysis and cell counts and FACS 
results for live lymphocytes defined as propidium iodide (Fluka) 
negative cells.
enzyme-linked immunosorbent assay 
(elisa)
Serum IgM and total IgGs were detected by ELISA. Briefly, Nunc 
ELISA 96-well plates were coated overnight with 2 µg/mL anti-
mouse IgM (Clone R331.24.12, in house made) or IgG (1030-01). 
After washings and blocking with gelatin, sera were incubated 1 h 
at 37°C followed by washings and secondary antibody incubation 
(1030-05 and 1020-05 for IgG and IgM, respectively). After wash-
ings, color was detected using TMB substrate reagent set (555214, 
BD) as recommended by the manufacturer. 450 nm optical densi-
ties were read on Victor3 Multilabel Counter fluorimeter (Wallac 
PerkinElmer, Turku, Finland), and results analyzed using Igor 
3.16 software. Purified mouse IgG (0107-01) and IgM (0101-01) 
at 2 and 0.5 µg/mL were used as standards. All antibodies were 
purchased from SouthernBiotech unless otherwise noticed.
Florescent-Based In Vitro recombination 
assay
Primary mouse embryonic fibroblasts (MEFs) derived from day 
14 WT and transgenic fetuses were isolated and infected by viral 
GFPi-mRFP particles (29). To induce RAG2 activity, 16 h postin-
fection cells were treated with 200 nM of 4-hydroxy-tamoxifen 
(TAM) dissolved in ethanol (etOH) to a final concentration of 2% 
etOH per well. Cells were analyzed by flow cytometry on a MoFlo 
FACS machine (Beckman Coulter).
resUlTs anD DiscUssiOn
Here, we present tamoxifen-inducible RAG1tg/RAG2tg-ER 
mouse models established in our laboratory. We describe the 
lines that were established on the C57/Bl6 background (hereafter 
Tg line), and when indicated crossed to an endogenous RAG2-
deficient background (hereafter Tg endoR2−/−).
FigUre 1 | rag transgenes are transcribed in lymphoid and non-lymphoid tissues of Tg mice. rag1, rag2 and β-tubulin transcripts were detected by RT-PCR in 
thymus, bone marrow, liver, lung, kidney, and brain from one wild-type (WT) and two Tg endoR2+/+ mice. Primers endo/tg detect both endogenous and transgenic 
rag transcripts. Results are representative of three independent experiments analyzing five different mice.
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Rag Transgenes are Ubiquitously 
expressed In Vivo
We first confirmed that the rag transgenes are expressed ubiqui-
tously in the transgenic mice. Given that the ER-system impedes 
RAG2 functionality but not expression, there is no need for TAM 
induction to observe the transcripts of the rag2-ER transgene. 
RAG1 and RAG2 expressions were determined by reverse 
transcription and PCR. Figure 1 shows the transcription levels 
of two Tg and one WT animals in the thymus, bone marrow, 
liver, lung, kidney and brain, for the endogenous and transgenic 
rag transcripts and for the beta-tubulin as a control. Note that 
the primers used for endogenous rag mRNA amplification also 
amplify the transcript encoded by the transgene (endo/tg, see 
Table S1 in Supplementary Material for sequences). As expected, 
rag transcripts are detected in thymocytes and bone marrow of 
both WT and Tg mice, while only the transgenic rag transcripts 
are observed in non-lymphoid tissues, and in all of them, con-
firming that RAG1tg and RAG2tg-ER are ubiquitously expressed 
(Figure 1).
Upon TaM-induction, rag2-ER Transgene 
rescue rag2-Deficiency for lymphoid 
Differentiation
In vivo functional analysis of the RAG1tg and the RAG2tg-ER 
was performed by complementation of lymphocyte deficiency of 
the Rag2-knock out mice (Tg endoR2−/−).
We asked whether the TAM-inducible model was functional 
in  vivo. We determined the phenotype of the mice using flow 
cytometry, by the characterization of the lymphoid compartment 
in absence of TAM-induction (Figure 2A, third column). First, 
cell numbers in the thymus from Tg endoR2−/− are very low (in 
average 3 million cells and in any case below 8 million cells; see 
Figure 2B), as for RAG-deficient mice. Flow cytometry analysis 
of the cell surface markers of lymphoid tissues was assessed 
as previously (26), to describe the differentiation profiles. We 
analyzed the development of thymocytes and early B cells in the 
thymus and the bone marrow, respectively, and the mature lym-
phocytes axillary lymph nodes (Figure 2A). As determined by 
the CD4/CD8 profiles, the Tg endoR2−/− line exhibits a complete 
block of development at the CD4−CD8− (DN) stage, similar to the 
R2−/− line. Additionally CD44/CD25 profile in the DN population 
shows a block at the DN3 stage, as for the R2−/− line. Similarly, 
there are no mature B cells (fractions E and F Figure 2A middle 
panels), and a fewer CD19+ cells are observed in Tg endoR2−/− 
line compared to WT, as in the R2−/− background. Consequently, 
neither mature T nor B  cells are detected in the lymph nodes 
compartment (Figure 2A, bottom lines).
To test the effect of TAM on the lymphoid compartment, WT, 
R2−/− and Tg endoR2−/− mice were fed with TAM containing 
food during 4 weeks before analysis. Mice were mildly affected by 
TAM as indicated by a weight-loss of 5–7%, irrespectively of their 
genotype (not shown). TAM administration to Tg endoR2−/− mice 
induces the maturation of thymocytes as attested by the number 
of thymocytes (Figure  2B) and the presence of DP and SP in 
the thymus and the peripheral organs (Figure 2A right panels). 
Also gamma-delta T cells were observed at similar ratios as in 
WT (Figure S1 in Supplementary Material). Consistent lower 
numbers of thymocytes in Tg endoR2−/− TAM+ animals when 
compared to WT mice, suggests lower activity of the induced rag2 
transgene than the endogenous recombinase genes (Figure 2B).
Treatment with TAM also induced mature B cells differentia-
tion in Tg endoR2−/− mice, found in the bone marrow (as attested 
by the presence of fraction E/F cells, i.e., IgM+ cells) and in the 
lymph node (with IgM+ and IgD+ cells), and frequencies of 
CD19+ cells were partially restored (Figure 2A middle panels). 
Nevertheless, the proportion of IgM+ cells was much lower in 
the bone marrow of Tg endoR2−/− TAM+ than in WT animals 
(3.7 versus 25.5%; see Figure 2A). We asked if there would be an 
impact on circulating antibodies levels in the sera of these ani-
mals, and we measured circulating Ig levels by ELISA. Figure 2B 
bottom left plot shows that treatment of Tg endoR2−/− by TAM 
overall rescued IgM and IgG production, with a large distribution 
of Ig levels, but not significantly different when compared to WT 
animals (p-value > 0.1). We conclude that induction of the rag2 
transgene by tamoxifen rescues the production of circulating 
antibodies in the sera of RAG2-deficient mice.
Altogether, these results show that the RAG1tg/RAG2tg-ER 
mouse model is inducible in vivo and successfully complement a 
null mutation for B and T cell development.
FigUre 2 | 4-Hydroxytamoxifen (TAM) induction of Tg endoR2−/− partially restores lymphocyte development. Young adult Tg-endoR2−/− mice (Tg endoR2−/−) were 
fed with normal (−) or TAM (+) food during 4 weeks before analysis. Untreated wild-type (WT) and recombination activating gene 2 (RAG2)-deficient (R2−/−) mice 
served as control. (a) Representative FACS profiles of thymocytes, bone marrow, and lymph nodes cells. (B) Full analysis of thymocytes numbers and frequency of 
thymic DP (upper panels); frequency of E and F fractions and CD43+ B cells in the bone marrow (middle panels); concentration of seric Ig and lymphocyte numbers 
in lymph nodes (bottom panels). *, **, and *** stand for p-values <10−2, 10−3, and 10−5, respectively. Results are representative of six independent experiments.
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Persistence of rag activity in the Thymus
We then asked if RAG activity is persistent in transgenic ani-
mals, and analyzed the Jα repertoire of the TCRα locus, which 
undergoes successive secondary rearrangements during the DP 
stage of thymocytes development (36). This particularity results 
in a bias of Jα usage in favor of the 5′ available gene segments 
when extra cycles of secondary rearrangements are allowed. We 
determined the Jα usage frequency of pooled cDNA from three 
Tg endoR2−/− fed with TAM food during 4  weeks, and deter-
mined the frequency of Jα gene segments usage as described in 
TaBle 1 | Sequences of six TCRα coding joints exhibit the features of the RAG-mediated signature.
rearrangement 5′ sequence n/P 3′ sequence
TRAV13-TRAJ39 ACTCAGGCACTTATCTCTGTGCTATGG – – CCCC –GAATAATAATGCAGGTGCCAAGCTCACATT
TRAV4-TRAJ56 ACTCAGGCACTTACTTCTGTGC – – – – TGCTGCGC  – – – CTGGAGGCAATAATAAGCTGACTTT
TRAV4-TRAJ56 ACTCAGGCACTTACTTCTGTGCTG – – – CTGCGC  – – – CTGGAGGCAATAATAAGCTGACTTT
TRAV4N-4-TRAJ58 GCGACTCAGCCAAGTACTTCTGTGC – – – CCCCCCGGG  – – – –AGGCACTGGGT_TAAGCTGTCATT
TRAV17-TRAJ58 CTCAGCCAAGTACTTCTGTGCACTGGAGGG CCGAG  – – – AAGGCACTGGGTCTAAGCTGTCATT
TRAV17-TRAJ58 CTCAGCCAAGTACTTCTGTGC – – – – – TGCCCCCCCGGG  – – – –AGGCACTGGGTCTAAGCTGTCATT
FigUre 3 | The T cell receptor (TCR) Jα repertoires of 4-hydroxytamoxifen (TAM)-induced Tg endoR2−/− and wild-type (WT) mice are significantly different. 
Tg-endoR2−/− mice (TgendoR2−/−) were fed with normal TAM (+) food during 4 weeks before analysis. PCR and HTS sequencing of TCRα rearrangements were 
performed and represented as follow: each dot is a rearrangement, and the x-axis represent the distance between the Jα used in the rearrangement and the 
constant (C) region. The doted vertical bars represent the average distances to (C) of the Jα used in rearrangement in TAM-induced Tg endoR2−/− (upper boxplot) 
and WT mice (bottom boxplot, from Mancini et al.). *** stands for a p-value <10−4.
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Mancini et al. (31), and using HTS (see Materials and Methods). 
We compared the repertoire obtained for the Tg endoR2−/− mice 
with the Jα repertoire of WT described in Mancini et  al. and 
observed a significant bias for the Jα segments that are more 
proximal to the constant region in transgenic mice (Figure  3, 
p < 0.001). Of note, we also monitored Jα usage in WT mice by 
individual cloning (22 rearrangements sequenced), and observed 
a similar repertoire as described in Mancini et al. (p = 0.28, data 
not shown). Analysis of the sequences of TCRα rearrangements 
from Tg endoR2−/− from TAM-induced mice showed a RAG/
NHEJ-mediated recombination signature, with deletion of CE 
nucleotides, addition of de novo nucleotides rich in C/G bases 
and with potential palindromic nucleotides, as shown on Table 1. 
These results indicate that RAG2tg activity is persistent after the 
DP stage and enable efficient secondary recombination of the 
TCRα locus.
Transgenic rag activity Promotes also 
illegitimate rearrangements
The development of B and T cells is only partially restored in Tg 
endoR2−/− animals induced for 4 weeks with TAM (see Figure 2). 
We next asked whether RAG activity from transgenic origin 
was sufficient to induce illegitimate recombination, and tested 
the described Bcl11b cryptic rearrangement to this end (see 
Figure 4A). We amplified the cryptic rearrangements in WT ani-
mals and in three Tg mice induced by TAM for 4 weeks. We used 
fluctuation PCR of total thymocytes DNA to assess frequencies 
of Bcl11b recombination which was similar in WT (25 rearrange-
ments per million thymocytes) and RAG-competent Tg animals 
(27.7 rearrangements per million thymocytes), and in the range 
of frequencies documented previously [23–50 rearrangements 
per million thymocytes in Ref. (37) and Ref. (33), respectively; 
data not shown].
We then observed that Bcl11b cryptic rearrangements were 
also detectable in two Tg endoR2−/− animals induced by TAM, 
albeit approximately 10 times less frequently than in WT [(33, 
37); Figure 4B; Table 2]. Such cryptic rearrangements were not 
detected in the 1 million cells equivalent DNA tested for the third 
Tg endoR2−/− TAM+ animal (Figure  4). These results indicate 
that cryptic recombination does occur in transgenic animals, and 
therefore that 4 weeks of transgenic RAG activity is sufficient to 
induce illegitimate recombination.
Upon TaM-Weaning, Transgenic rag 
activity ceases
We then tested whether the induction of RAG2tg-ER was 
reversible. We administrated TAM to Tg endoR2−/− mice during 
2 weeks, after what we switched for normal food. As a control, 
FACS profiles of thymus and bone marrow analyses from a Tg 
endoR2−/− mouse right after 2 weeks of TAM administration (see 
Figure 5, left panels) show mostly DP thymocytes, though imma-
ture single positives cells start appearing (around 1%). The pres-
ence of mature fractions E to F cells attests for B cell development. 
These results show that a period of 2 weeks of TAM is sufficient to 
TaBle 2 | Coding joints sequences of Bcl11b cryptic recombination events exhibit the features of the RAG-mediated signature.
5′ sequence n/P 3′ sequence
GGGCACTAACAAGGAAAGAAATTAATCTCA TT  – – TGTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTAATCTCA GA TGTGTGTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTAATCTCA TT  – – – – – – TGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGGAAGAAATTAATCT – -  – – – TCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTAATC – – C  – -GTGTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTAA – – – ACCGTT  – – TGTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTA – – – TCCACGGTT  – – TGTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATT – – – – CCCTGAG  – – –GTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATT – – – – -  – – – – – – –GTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTA – – – TCTC  – – – – – – –GTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTAATCTC– TTCAA TGTGTGTCTGTGTGTCTTGGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAA – – – – – CCC  – – TGTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTAATCTCA GA TGTGTGTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTAATC – – –GTGTGTCTGTGTGTCTGTGTGTCCCTTCTA
GGGCACTAACAAGGAAAGAAATTAATCT – -  – – – TCTGTGTGTCTGTGTGTCCCTTCTA
FigUre 4 | Occurrence of Bcl11b cryptic recombination in 4-hydroxytamoxifen (TAM)-induced Tg endoR2−/− animals. (a) Bcl11b locus, cryptic recombination sites 
and nested primers used in the fluctuation PCR analysis. Bcl11b exons are represented by red boxes, with introns represented as dashed lines connecting these 
boxes (note that bcl11b is on the reverse strand); cRSS are depicted as triangles within the introns, and primers used for the nested PCR are depicted by arrows. 
The bottom line shows an illegitimate Bcl11b recombination. (B) Fluctuation PCR analysis for each mouse concerned 24 reactions, each with 240 ng of genomic 
DNA, equivalent to a total of 0.96 million cells. Each row is the analysis of the total thymocytes of one Tg endoR2−/− TAM+ mice. Recombination was detected in two 
out of three mice, at the frequency indicated in the right column.
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induce B and T cell differentiation beyond the blockade induced 
by RAG deficiency.
Tamoxifen elimination half-life is about 5–7 days in human, 
but may be up to 21 days (38). We carried the TAM-deprivation 
period (TAM-OFF) during 1 month and mice were sacrificed at 
the termination point of the experiment (6.5 weeks postinduc-
tion, right panels in Figure 5A).
The CD4/8 profile of Tg endoR2−/− animals revealed no or very 
few thymocytes and also showed persistent SP cells (Figure 5). 
The FACS profiles also revealed a block of development at the 
DN3 stage, as seen for the R2−/− line (Figures 1A and 5, CD44/25 
profile). Likewise, bone marrow cells exhibit few IgM+ cells and 
show a reduced frequency of CD19+ cells, although the block at 
the CD43+CD19+ is not marked (Figure 5). Similar results were 
observed for the two other mice of the same experiment and for 
three animals induced 1 week with TAM followed by 3 weeks of 
normal food before sacrifice and analysis of lymphoid organs 
(data not shown and Figure 5B).
All in all, this analysis reveals that the functionality of the RAG2 
proteins from transgenic origin can be interrupted by weaning off 
tamoxifen, and that the inducible system we developed is also 
reversible.
FigUre 5 | Termination of 4-hydroxytamoxifen (TAM) administration prevents further lymphocyte development. (a,B) The upper lines represent the timelines of 
normal and TAM food administration in Tg endoR2−/− animals, arrows indicate the time at analysis. (a) Administration of TAM during 2 weeks is sufficient to induce 
mature lymphocytes differentiation (left panels), while withdrawal of TAM for 4 weeks arrests lymphoid development. Representative FACS profiles of developing 
T cells in the thymus (upper panels) and B cells in the bone marrow (bottom panels). Data are representative of 3 independent experiments. (B) B cell development 
precedes T cells differentiation. Representative FACS profiles of B220+ peripheral blood mononuclear cell (PBMC, upper panels) and Thy1+ (lower panels) cells, after 
1 week of TAM administration (D7) or followed by 1, 2, or 3 weeks of normal food. IgM+ and IgD+ B cells are observed from the first week of analysis, while only a 
few CD4+ cells are detected at that stage. Clear CD4+ and CD8+ T cells populations are detected at day 28. Data are representative of three independent 
experiments. (c) B cells consistently appear before T cells in peripheral blood. Kinetic analysis of B and T cells frequency in blood of Tg endoR2−/− animals treated 
along the (B) regimen (N = 11 mice).
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The inducible rag-activity system as a 
Model for the analysis of T and B cell 
Development Kinetics
During the experiment in which Tg endoR2−/− mice were fed 
on TAM during 1  week followed by 3  weeks of normal food 
(Figure  5B), a sample of peripheral blood was analyzed every 
week for the presence of B and T cells. PBMC analysis showed 
that 1 week of TAM induction was sufficient to observe mature 
lymphoid cells in the peripheral blood (Figure 5C). This analysis 
also revealed that B  cells appeared earlier than T  cells (about 
2 weeks earlier), and that among T cells, CD4+ appeared before 
CD8+ single positive T cells, a result consistent in 4 independent 
experiments analyzing 11 mice. The development of thymocytes 
from DN1 to DP (after TCRα recombination) takes about 7 or 
8 days (39), a time scale similar to that required for peripheral 
FigUre 6 | Alternated on and off 4-hydroxytamoxifen (TAM) administration 
reduces toxicity and promotes completion of the Vbeta repertoire. (a) Tg 
endoR2−/− mice were treated for 16 weeks with alternate periods on (+) and 
off (−) TAM food (upper scheme), and body weight kinetics established along 
the treatments. (B) By week 16 of the alternate treatment in (a), thymocytes 
were analyzed by FACS, and wild-type (WT) thymocytes served as control. 
Shown is the proportion of Thy1+ thymocytes expressing each of the 8Vβ 
tested.
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B cell to be detectable in our system. It is also well established 
that migration through thymic epithelial cortex and medulla 
associates with step wise selection events purging nascent T cells 
in a much more severe manner than what is measurable for the B 
lineage in the bone marrow. Absence of DP in the thymus from Tg 
endoR2−/− mice fed for 1 week with TAM food (data not shown) 
indicates that the delay is anterior to migration to the periphery, 
and in turn suggests that rearrangements are more efficient at the 
Ig than at the TCRαβ loci.
Finally, upon TAM weaning, B  cells vanished earlier than 
T cells (see day 28 in Figure 5B), in agreement with the poorer 
lymphopenia-induced proliferative capacity of mature B than 
T cells. We observed some discrepancies between individuals as 
to the timing of mature cells appearance and the amount of B 
and T cells in the PBMC, which might be due to differences in 
TAM intake between mice. However, we could not correlate low 
number of mature cells in the periphery with high weight loss 
(i.e., with tamoxifen-intake).
Transgenic rag activity can Be 
Maintained
As mice loose weight under TAM treatment (up to 10% of total 
weight per week), we optimized the system to improve animal 
welfare while maintaining RAG2tg activity. Therefore, we let 
mice feed on TAM during 4 weeks and then alternated between 
TAM and normal food (see Figure 6A upper line). The weight of 
animals was systematically increasing and decreasing during nor-
mal versus TAM periods, respectively (Figure 6A). The presence 
of B and T cells in peripheral blood was observed through the 
full duration of the experiment until week 16 (data not shown), 
and thymus and bone marrow from the animals at the termina-
tion point exhibit similar profiles as described in Figure 2, with 
mature B and T cells in the bone marrow and thymus, respec-
tively, as well as in the lymph nodes (Figure S2 in Supplementary 
Material), showing that alternation between normal and TAM 
food is enough to maintain RAG-activity. Additionally, the Vβ 
repertoire of these three transgenic mice was normal, since the 
expression of the 8Vβ in Thy1+ thymocytes from the three Tg 
endoR2−/− mice was similar to the WT repertoire (Figure 6B). Of 
note, the repertoire in WT animals was strikingly similar to that 
observed previously (30, 40).
a Model of rag Overexpression
In addition to the transgenic model described above, which was 
generated directly on a C57/Bl6 background, two transgenic lines 
initially generated on the Fvb background were backcrossed to 
the C57/Bl6 background. One of these presented a phenotype 
similar to those described above (data not shown), while the 
other differed for several features. Here, we describe the latter 
transgenic line, which we refer to as the Tghi line.
We analyzed thymus and bone marrow cells of Tghi endoR2−/− 
mice maintained under normal food. Unexpectedly, DP and SP 
thymocytes, as well as IgM+ B cells (Figure 7A left panels) were 
readily detectable. Consistently with these results, Tghi endoR2−/− 
mice present bigger thymi than R2−/− mice, which was confirmed 
by thymocyte count (Figure 7B). Furthermore, seric IgG and IgM 
were detectable in Tghi endoR2−/− mice (Figure 7C; Figure S3A in 
Supplementary Material). Genotyping data suggested higher copy 
number, and RT-PCR analysis supported more abundant tg-rag1 
and tg-rag2ER transcripts in this Tghi line when compared to the 
two others transgenic lines produced (not shown). We conclude 
that the Tghi line presents leakiness, likely related to the inefficient 
cytoplasmic retention of overexpressed RAG2-ER protein, and 
as reported previously for specific ERT fusion transgenes [e.g., 
Ref. (41)].
Treatment with TAM food, further enhanced B and T  cell 
development in Tghi endoR2−/− mice, as indicated by increased 
frequency of mature T and B  cells and increased thymocytes 
numbers, reaching for some mice values similar to those observed 
in WT mice (second column of panels on Figures  7A,B). The 
high variability in thymocytes number was not age-related and 
may be a consequence of variable TAM intake, or else related to 
tgRAG toxicity, as evidenced below.
We also bred the Tghi line on the RAG2-competent background. 
We observed similar FACS profiles, as well as similar number of 
thymocytes between these mice and WT animals (Figure  7A 
third column and Figure 7B). Interestingly, TAM induction of 
Tghi (RAG-competent) mice resulted in a significant reduction 
of thymocytes numbers compared to WT and non-induced 
FigUre 7 | The Tghi line is leaky and exhibits impaired lymphocyte development/maintenance. Tghi endoR2−/− and Tghi endoR2+/− mice were induced (TAM+) or not 
(TAM−) for 4 weeks before analysis. Wild-type (WT) and Rag2−/− mice served as control (a) Representative FACS analysis of thymocytes, bone marrow, and lymph 
nodes in Tghi mice. (B) Total thymocytes numbers. Tghi endoR2−/− TAM-mice have higher number of thymocytes than R2−/− mice, and Tghi endoR2+/− mice exhibit a 
significant decrease of thymocytes when treated by TAM (*p = 0.016 and ****p < 0.0001 compared to untreated Tghi endoR2+/− and WT mice, respectively). (c) Serum 
IgG concentration was assessed by quantitative enzyme-linked immunosorbent assay (ELISA). Tghi mice, whether endoR2−/− or +/−, present significantly lower seric IgG 
levels than WT animals (*p = 0.03 untreated Tghi endoR2−/−, and **p = 0.008 TAM+ Tghi endoR2+/− mice, respectively). (D) Frequency of γδ T-cells in thymocytes was 
determined by FACS analysis. No statistical differences were found between the different groups. (e) Absolute number of mature T and B cells in pooled lymph nodes 
reveals severe lymphopenia in Tghi mice, irrespective of functional endoRag2 or TAM treatment. Results are representative of six independent experiments.
10
Bonnet et al. iRAGu: Inducible RAG-Transgenic Mouse Model
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1525
Tghi mice (p < 0.0001 and p = 0.016, respectively), a feature not 
observed for the RAG-competent Tg line described in Sections 
“Description of the Constructs” to “Transgenic RAG Activity 
Can Be Maintained” (Figure S3C in Supplementary Material). 
This reduction was associated with a lower frequency of DP cells 
(Figures 7A,B and D; Figure S3B in Supplementary Material) 
and quasi absence of T  cells in the periphery (Figure  7E). 
The population of B220+ IgM+ (fractions E and F) in the bone 
marrow was also significantly reduced (p =  0.01, Figure S3D 
in Supplementary Material). Finally, the levels of total IgM and 
IgG in the sera of TAM-induced Tghi mice were very low and 
similar to those observed in RAG2-deficient animals (Figure 
S3A in Supplementary Material; Figure  7C). These results 
strongly suggest a deleterious effect of RAG over-expression (i.e., 
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endogenous plus transgenic) on B and T cell development, as we 
had discussed in our previously reported model of constitutive 
RAG1 and RAG2 overexpression (26).
We next asked if the transgenic recombinase was functional 
in non-lymphoid cells. We used 14 days MEF from Tghi animals 
and confirmed they express the transgenes (Figure  8A). For 
functional assay, we took advantage of the GFPi reporter of 
RAG activity we developed earlier (29). This assay allows to 
quantify RAG activity through the expression of GFP, itself con-
ditioned by an event of RAG mediated inversion. The construct 
also contained mRFP, which serves as a marker of efficient gene 
transfer. WT and Tghi MEF were infected by GFPi viral particles 
and treated during 3  weeks either with ethanol (etOH), as a 
negative control, or with TAM. FACS analysis revealed the 
presence of GFP+ cells in transgenic MEF under TAM induc-
tion, with levels of GFP expression increasing with time of 
induction (Figure 8B; Figure S4A in Supplementary Material). 
Non-induced Tghi MEF exhibit low levels of GFP expression, 
confirming the leakiness of the transgene in this mouse line. 
Of note, infected MEF from the non-leaky Tg line exhibit up 
to 5% of GFP expression after 3  weeks of induction (versus 
20% for the Tghi MEF, Figure 8B; Figure S4B in Supplementary 
Material), while no GFP expression was observed without 
TAM-induction. Altogether, these data confirm that rag1 and 
rag2-ER are functional transgenes in a non-lymphoid tissue, 
and that this activity is TAM-inducible.
FigUre 8 | 4-Hydroxytamoxifen (TAM)-induction of recombination activating gene (RAG) activity in non-lymphoid organs. (a,B) Mouse embryonic fibroblasts (MEF) 
cultures were established from Tghi and wild-type (WT) fetuses. (a) RT-PCR analysis revealed readily detectable Tg rag1and Tg rag2-ER transcripts in Tghi MEF. (B) 
RAG activity was assessed using the GFPi recombination assay. Upon infection with viral GFPi-mRFP particles, transgenic MEF were treated with either 2% ethanol 
(etOH) or 2% ethanol containing 200 nM of 4-hydroxy-tamoxifen (TAM) during 3 weeks. GFP expression revealed by FACS analysis accounts for induced RAG 
activity. Results are representative of two independent experiments. (c) The upper scheme represents alternated on and off TAM administration during the 49 weeks 
duration of the experiment. The graph shows survival of R2−/− (gray dotted line) and Tghi (black line) mice reconstituted with R2−/− bone marrow. Life span was not 
significantly different between the groups. N = 6 for each group.
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